Cypress Biosciences (CYPB)

Cypress Biosciences (<a href=&quot;javascript:void(0)&quot; onclick=&quot;quotepop(&#39;cypb&#39;)&quot;>CYPB</a>) - With a data from a third positive phase III trial in fibromyalgia released in early December 2008, we are feeling confident that the FDA will approval Cypress Bioscience&#39;s and partner Forest Labs&#39; milnacipran product during the first quarter of 2009. <p> Approval of milnacipran will be a transformational event for Cypress. The company should become almost immediately profitable based on royalties from Forest Labs. By 2013 we see total revenues exceeding $110 million, with net margins above 50%. <p> We see fair value at $12 per share, or 25x our 2012 EPS estimate of $1.12 per share, discounted back to present day.

Comments

• Enhanced Categores

  • Analyst Opinions (34337)
  • ETF Picks (170)
  • Mergers and Acquisitions (3683)
  • Stock Picks (1587)
  • Stocks to Sell (708)
  • Uncategorized (61)

• Archives

  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008

• Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

• Pages

  • About Us
  • Contact Us

• 
  

• About

  StockPickBloggers.com brings you the hottest stock picks from the investment community.

• Blogroll

  • Bear of the Day - Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners.
  • Bull of the Day - Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners.
  • Hot Stock Picks - Hot stock picks from the stock market neural network scan of Stocknod.com. Get today’s best stock picks from the leader in stock picks analysis.
  • Investools
  • MarketRiders Blog - How To Become A Better Investor
  • Marketwire – Mergers and Acquisitions - Marketwire – Mergers and Acquisitions
  • Motley Fool
  • Seeking Alpha
  • The Stock Advisors - Explore the world of financial newsletters.  For years, independent newsletter advisors have provided their subscribers with better returns than most other sources.  Most of the greatest stock pickers in the world allow us to reprint stock recom
  • The StockCharts.com Market Message - Get exclusive commentary on what’s going on in the market at Stockcharts.com. The Market Message is a paid service, for information regarding signing up please visit http://stockcharts.com.
  • US Economy & Stock Market Analysis with Stock Picks & Free Investing Tips - Stay Connected – Never miss trade
  • Zack's Analyst Opinions - Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners.